Discounted Cash Flow
Biocryst Pharmaceuticals Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $26.4m | $-55.1m | $-58.7m | -209.3% | $-0.75 |
| 2017 | $25.2m (-4.4%) | $-65.8m (-19.3%) | $-41.5m (29.4%) | -261.2% (-24.8%) | $-0.78 (-4.0%) |
| 2018 | $20.7m (-18.0%) | $-101.3m (-53.9%) | $-92.9m (-124.1%) | -490.3% (-87.7%) | $-0.98 (-25.6%) |
| 2019 | $48.8m (136.5%) | $-108.9m (-7.6%) | $-89.9m (3.2%) | -223.0% (54.5%) | $-0.94 (4.1%) |
| 2020 | $17.8m (-63.5%) | $-182.8m (-67.9%) | $-137.7m (-53.2%) | -1026.4% (-360.3%) | $-1.09 (-16.0%) |
| 2021 | $157.2m (782.4%) | $-184.1m (-0.7%) | $-144.5m (-4.9%) | -117.1% (88.6%) | $-1.03 (5.5%) |
| 2022 | $270.8m (72.3%) | $-247.1m (-34.3%) | $-163.2m (-12.9%) | -91.2% (22.1%) | $-1.33 (-29.1%) |
| 2023 | $331.4m (22.4%) | $-226.5m (8.3%) | $-97.3m (40.4%) | -68.4% (25.1%) | $-1.18 (11.3%) |
| 2024 | $450.7m (36.0%) | $-88.9m (60.8%) | $-53.1m (45.4%) | -19.7% (71.2%) | $-0.43 (63.6%) |
| 2025 | $874.8m (94.1%) | $263.9m (396.9%) | $344.9m (749.0%) | 30.2% (252.9%) | $1.26 (393.0%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.